单药控制血糖效果不佳的T2DM患者应用阿卡波糖、二甲双胍联合达格列净治疗的疗效

打开文本图片集

[中图分类号]R587.1 [文献标识码]A [文章编号]1672-4062（2026）02（a）-0081-04

Therapeutic Effect of Acarbose， Metformin Combined with Dapagliflozin in T2DM Patients with Poor Response to Monotherapy for Blood Glucose Control

CHENFen，WUYamei，LINYonghua

LichengDistrictHospitalofTraditionalChinese Medicine，Putian City，Putian3511Oo，Fujian，China [Abstract]Objective Toanalyzethe eficacyofacarbose，metformin combined with dapagliflozin inpatients with type 2diabetes melitus （T2DM） with poorglycemic controlby single drug.Methods From May2024 toMay2025，a total of 116 T2DM patients with poor glycemic control by single drug were conveniently seleted in Licheng District HospitalofTraditional Chinese Medicine，PutianCity.According todiferent treatmentmethods，they were divided into twodrug group （58 cases，treated with acarbose on the basis of single drug metformin）and three-drug group （58 cases， treated with dapagliflozinonthebasisof two-drug group）.After12weeksof treatment，theblood glucose，blood glucosefluctuation index and blood lipid index werecompared between the two groups，and the adverse reactions were observed.Results After treatment，the fasting plasma glucose，glycated hemoglobin Alc，maximum glucose fluctuation range and postprandialplasma glucose fluctuationrange of thetwo groups were lower than those before treatment，and the three-drug group was lower than the two-drug group，the differences were statistically significant （all P<0.05 ） There was no significant diference in total cholesteroland triglyceride levels between the three-drug groupand the two-drug group before and after treatment （all P>0.05 ）.There was no significant difference in the incidence of adverse reactions between the two groups （ P >0.05）.Conclusion Compared with acarbose combined with metformin，the triple therapy with dapagliflozin is more stable and safe in T2DM patients with poor glycemic controlby single drug.

[Keywords] Type2diabetesmellitus;Acarbose;Metformin;Dapagliflozin

2型糖尿病（type2diabetesmellitus，T2DM）是一种因遗传、环境等因素引发胰岛素分泌不足或胰岛素抵抗，导致患者血糖水平增高的慢性病，临床首选降糖药物二甲双胍，通过抑制肝糖原输出，增加外周组织对胰岛素的敏感性，减少肠道葡萄糖吸收，降低血糖[]。（剩余4181字）